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ABSTRACT:
Triple-negative breast cancer (TNBC) is characterized by unique aggressive 
behavior and lack of targeted therapies. Among the various molecular subtypes of 
breast cancer, it was observed that TNBCs express elevated levels of sphingosine 
kinase 1 (SPHK1) compared to other breast tumor subtypes. High levels of SPHK1 
gene expression correlated with poor overall and progression- free survival, as well 
as poor response to Doxorubicin-based treatment. Inhibition of SPHK1 was found to 
attenuate ERK1/2 and AKT signaling and reduce growth of TNBC cells in vitro and 
in a xenograft SCID mouse model. Moreover, SPHK1 inhibition by siRNA knockdown 
or treatment with SKI-5C sensitizes TNBCs to chemotherapeutic drugs. Our findings 
suggest that SPHK1 inhibition, which effectively counteracts oncogenic signaling 
through ERK1/2 and AKT pathways, is a potentially important anti-tumor strategy 
in TNBC. A combination of SPHK1 inhibitors with chemotherapeutic agents may be 
effective against this aggressive subtype of breast cancer.
INTRODUCTION
Triple-negative breast cancer (TNBC) accounts for 
about 15% of breast cancer cases and is characterized by 
absence of estrogen receptor (ER), progesterone receptor 
(PR) and HER2 receptors. It is associated with aggressive 
histology and poor prognosis with shorter survival 
compared to other subtypes of breast cancers [1-3]. These 
tumors tend to occur more often in younger women and 
African American women [4]. Unlike other types of breast 
cancer, neither hormonal therapy such as tamoxifen or 
aromatase inhibitors, nor targeted therapy against HER2 
using Herceptin (Trastuzumab), are effective against these 
neoplastic cells. 
TNBC has a more aggressive clinical course than 
other subtypes of breast cancer [5]. They are currently 
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treated with non-target specific chemotherapy such as 
Doxorubicin, 5-Fluorouracil (5-FU) and Docetaxel [6]. 
Doxorubicin is an anthracycline drug used in patients 
with metastatic breast cancer [7] but concerns include 
its relatively low therapeutic index and toxicities such as 
myelosuppression, immunosupression and cardiotoxicity 
[8]. 5-FU is also a widely used chemotherapeutic agent 
but is associated with cardiotoxicity, neutropenia and 
mucositis [9]. Docetaxel is a microtubule-stabilizing 
taxane that has higher antitumor activity compared to 
paclitaxel [10] but has been reported to cause toxicities 
such as neutropenia and fluid retention [11]. Taken 
together, treatment options for triple negative breast cancer 
remain limited and effective targeted therapies have yet to 
be developed [6].
Sphingosine kinases (SPHKs) are becoming 
established as critical mediators of oncogenesis [12]. 
Two isoforms of SPHK enzymes with distinct functions, 
SPHK1 and SPHK2, have been discovered [13, 14]. 
SPHK1, in particular, has been implicated in oncogenic 
roles in cancer, including proliferation, resistance to 
apoptosis and transformation [15]. Recent work in our 
laboratory revealed a positive correlation between SPHK1 
and advanced tumor progression and SPHK1 as a predictor 
for mortality in colon cancer patients [16]. SPHKs convert 
sphingosine to S1P, which acts as an intracellular second 
messenger and extracellular ligand for specific receptors 
[17, 18]. Secreted S1P in turn, acts as a ligand for the 
family of G protein-coupled S1P receptors 1 to 5 (S1PR1 
to S1PR5), and regulates a wide range of biological effects 
including transformation and migration [19]. 
Increased expressions of SPHKs have been observed 
in breast tumors [20] and microarray analysis suggests 
that breast cancer patients with high levels of the SPHK1 
isoform are predisposed to poorer outcomes [21]. Most 
studies to date have highlighted the roles of SPHK1 in 
ER-positive breast cancer and its interactions with the 
estrogen receptor. SPHK1/S1P signaling has been reported 
to confer endocrine drug resistance and also promote 
estrogen-dependent tumorigenesis, motility and survival 
of ER-positive breast cancer [22, 23]. However, despite 
previous evidence that higher SPHK1 levels are found in 
ER-negative tumors [21], the therapeutic implications of 
SPHK1 in TNBC have not been well explored. 
In this study, we examine the prognostic 
significance of SPHK1 in breast cancer and address the 
therapeutic potential of targeting SPHK1 in TNBCs, 
using SPHK1 knockdown experiments or treatment with 
a pharmacological SPHK1 inhibitor, 2,2-dimethyl-4S-
(1-oxo-2-hexadecyn-1-yl)-1,1-dimethylethyl ester-3-
oxazolidinecarboxylic acid (SKI-5C). Therapeutic effects 
of targeting SPHK1 on cell proliferation and cell death are 
evaluated upon SPHK1 inhibition alone or in combination 
with chemotherapeutic drugs. 
RESULTS
Upregulated SPHK1 expression in human breast 
cancer tissues 
We performed comparative analysis of SPHK1 
expression using real time polymerase chain reaction 
(RT-PCR) on breast tumor tissues and adjacent normal 
breast tissues of 32 patients. The expression of SPHK1 
mRNA was determined to be at least two folds higher in 
the breast tumor tissues compared to normal breast tissues 
in 62.5% of patients (20 of 32 cases) of (Fig. 1A). We 
observed that ER-negative tumors express higher SPHK1 
mRNA levels than ER-positive tumors (p=0.007, Fig. 
1B). Clinical data eg. grade, histology, ER/PR status of 
the patients can be found in Supplementary Data Table 
1.We also found that triple-negative tumors express 
higher SPHK1 mRNA compared to other breast tumors (p 
= 6.98801E-06, Supplementary Data Fig. 1A). Through 
gene expression analyses, breast cancer tumors have been 
classified into six molecular tumor subtypes based on 
hierarchical clustering (basal-like, claudin-low, luminal 
A, luminal B, HER2-enriched, normal-like), where triple-
negative tumors have been reported to be largely basal-
like [24]. Using human breast cancer microarray data from 
Affymetrix U133A and U133Plus2 platforms, we found 
that basal-like subtype exhibits the highest SPHK1 gene 
expression among the various molecular subtypes (Fig. 
1C). Mean and median values of SPHK1 gene expression 
are shown in Supplementary Data Table 2. Pair-wise 
comparison also shows significantly higher SPHK1 levels 
in the basal-like subtype compared to other molecular 
subtypes (Supplementary Data Table 3). 
When patients from a breast cancer cohort were 
categorized into SPHK1-low and high groups based on 
median expression of SPHK1 (7.34 for OS, and 7.32 for 
PFS) (Supplementary Data Fig. 2A), patient survival 
analysis revealed an inverse correlation between SPHK1 
expression level and the overall (OS) and progression-free 
survival (PFS) of breast cancer patients (p=0.0401 and 
p=0.0052 respectively) (Fig. 1D). Among the SPHK1-low 
and -high groups analysed for OS and PFS, it was found 
that the proportion of basal breast carcinoma patients in 
the SPHK1-high group was two to three times greater than 
the proportion of basal breast carcinoma patients in the 
SPHK1-low group (Supplementary Data Fig. 2B). Taken 
together, these observations suggest that high levels of 
SPHK1 expression are associated with poorer prognosis 
and lower survival in breast cancer.
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Figure 1:SPHK1 expression in breast tumors. (A) SPHK1mRNA expression in human breast tumors and paired adjacent normal 
breast tissues by real-time PCR. Expression levels were normalized with GAPDH. A two-tailed Student t-test was used to calculate statistical 
significance. (B) SPHK1 mRNA expression in ER-positive, ER (+), and ER-negative, ER (-) cases. Each dot corresponds to an individual 
patient’s fold change in relative SPHK1 mRNA levels between tumor and adjacent normal tissue. ER (-) patients showed significantly 
higher expression of SPHK1 than ER (+) patients (p = 0.007). (C) SPHK1 gene expression levels in breast cancer subtypes. Basal subtype 
has the highest SPHK1 gene expression (Mann Whitney Test, p = 4.16e-81), whereas Luminal-A and –B subtypes have the lowest SPHK1 
gene expression (Mann Whitney Test, p = 1.1e-21, and p = 6.74e-37, respectively). (D) SPHK1 gene expression correlates with poor overall 
(left) and progression-free survival (right). Kaplan-Meier plots of overall and progression-free survival in all samples. Median expression 
was used to define SPHK1-Low and SPHK1-High. The p-value shown was computed by log-rank test. HR indicates the hazard ratio, and 
n in parentheses indicates number of samples. 
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Upregulated SPHK1 expression in human breast 
cancer cell lines
To determine SPHK1 expression in human breast 
cancer cell lines, real-time PCR and Western blots were 
performed on samples derived from five breast cancer 
cell lines and a breast epithelial cell line (MCF-10A). 
Real-time PCR showed that SPHK1 mRNA expression 
was higher in breast cancer cell lines compared to MCF-
10A (Fig. 2A). Both SPHK1 protein expression and 
SPHK1 activity were also higher in breast cancer cell 
lines compared to MCF-10A (Fig. 2B-C). Among the 
breast tumor cell lines, the metastatic and triple-negative 
MDA-MB-231 cells exhibited the highest SPHK1 protein 
expression and the most pronounced SPHK1 activity. On 
the contrary, while there was no significant difference in 
SPHK2 mRNA expression in breast cancer patient data 
(Supplementary Data Fig. 1B), SPHK2 mRNA expression 
was lower in breast cancer cell lines compared to normal 
epithelial cell line MCF-10A (Supplementary Data Fig. 
1C).
Inhibition of SPHK1 activity induces apoptosis 
and inhibits proliferation of breast cancer cells 
We investigated the effects of inhibiting SPHK1 
activity using the SPHK1 pharmacological inhibitor, 
SKI-5C, on the cell cycle kinetics of triple-negative 
MDA-MB-231 and ER-positive MCF-7 cells. Cell cycle 
analysis by PI staining of MDA-MB-231 cells indicated 
that the induction of growth arrest by 10µM SKI-5C 
Figure 3:Inhibition of SPHK1 activity induces apoptosis 
and inhibits proliferation of breast cancer cells. (A) 
Flow cytometric analysis of PI staining in MDA-MB-231, MCF-
7 and MCF-10A cell lines fixed after treatment with 10-50µM 
SKI-5C for 24 hours. The graph shows percentages of cells in 
the Sub-G1 fraction for MDA-MB-231, MCF-7 and MCF-10A. 
Data represents the mean ± SD of at least three independent 
experiments; *p < 0.05. (B) MDA-MB-231 and MCF-7 cells 
were treated with 10-25µM SKI-5C for 24 hours and apoptotic 
cells were detected by flow-cytometric analysis of Annexin 
V staining. Data represents the mean ± SD of at least three 
independent experiments; *p < 0.05. (C) The effect of SKI-5C 
on cell proliferation was determined by culturing MCF-7, MDA-
MB-231 and MCF10A cells under standard culture conditions 
in the presence of 10µM SKI-5C for 6 to 48 hours by BrdU 
assay. The relative fold changes in O.D. at 450nm compared to 
cells at the start of the assay (‘0’ hours) are shown, indicated as 
‘Relative Proliferation’ on the y-axis. Data represents the mean ± 
SD of at least three independent experiments; *p < 0.05.
Figure 2:SPHK1 expression in breast cancer cells. (A) 
SPHK1 mRNA levels by real-time PCR in breast cancer cell 
lines and the breast epithelial cell line MCF10A (normalized to 
GAPDH). The data is expressed as the fold change in SPHK1 
expression compared to MCF-10A. Data represents the mean ± 
SD of at least three independent experiments; *p < 0.05. (B) 
The protein expression of SPHK1 in breast cancer cell lines was 
determined by Western blot. (C) Endogenous SPHK activity 
in cell lines. Data represents the mean ± SD of at least three 
independent experiments; *p < 0.05.
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was associated with the accumulation of cells in sub-G1 
phase. At higher doses of 25uM and 50uM SKI-5C, cell 
death was predominant with increases in the sub-G1 
population to 43.05% and 50.98% respectively. MCF-
7 cells also induced a dose-dependent increase in the 
sub-G1 population upon exposure to SKI-5C (Fig. 3A and 
Supplementary Data Fig. 3A). Significant increases in the 
percentages of sub-G1 populations were observed in both 
MDA-MB-231 and MCF-7 cells at 25µM and 50µM SKI-
5C. In contrast, normal epithelial MCF-10A cells were 
less sensitive to SKI-5C, with no significant increases 
in sub-G1 population at doses lower than 50µM SKI-5C 
(Fig.3A). We further investigated the effects of SKI-5C 
on induction of apoptosis by Annexin V staining. There 
was a dose-dependent increase in apoptosis of MDA-
MB-231 and MCF-7 cells within 24h, with 63.29% of 
MDA-MB-231 cells and 35% of MCF-7 cells undergoing 
apoptosis when treated with 25µM SKI-5C (Fig. 3B). 
These data indicate that the survival of breast cancer cells 
is significantly compromised by SPHK1 inhibition. 
Figure 4: Inhibition of SPHK1 activity impairs colony formation and breast tumor formation by MDA-MB-231 cells in 
immunodeficient mice. (A) Top: Representative western blot of SPHK1 and GAPDH in MDA-MB-231 after transfection with SPHK1-
specific siRNAs (SPHK1 siRNA1 and siRNA2) or control siRNA for 48 hours. Bottom: Representative images of colony formation assay 
in MDA-MB-231 cells transfected with either control siRNA or SPHK1 siRNAs. 48 hours after transfection, equivalent numbers of live 
cells were replated, cultured for 7 days, then stained with crystal violet. (B) Number of colonies from (A) were counted. Data are expressed 
as mean ± S.D. of triplicate measurements and of three independent experiments; *p < 0.01. (C) The effect of SKI-5C on colony formation 
was determined by treating MDA-MB-231 breast cancer cells grown at low cell density (1000 cells/well in a 6-well plate) with 5 - 25µM 
SKI-5C for 7 days. Colonies were stained with crystal violet and quantified. Data are expressed as mean ± S.D. of triplicate measurements 
and of three independent experiments; *p < 0.01. (D) SCID mice (6 mice per group) with palpable MDA-MB-231 tumors (2 tumors per 
mouse) were injected intraperitoneally with saline (control) or SKI-5C 1 or 10mg/kg body weight for 14 consecutive days. Tumor volumes 
were recorded daily. Animals were euthanised and tumors excised. (E) Representative picture shows MDA-MB-231 tumors treated with 
saline control or with SKI-5C at 10mg/kg body weight. Animals were euthanised and tumors excised and weighed. SKI-5C inhibits tumor 
growth and reduces tumor weight in a dose-dependent manner. Data are expressed as mean ± S.D. (F) Tumor histology. Paraffin-embedded 
tumor sections were stained with either H&E or PCNA. Apoptotic cells were visualized by TUNEL staining and counterstained with methyl 
green. Slides were analyzed by fluorescence microscopy. Representative section from n=3 individual treated tumors. Scale bar represents 
50 µm.
Oncotarget5925www.impactjournals.com/oncotarget
In addition, the effects of SPHK1 inhibition by 
SKI-5C on the proliferation of breast cancer cells were 
examined by BrdU assay. 10 µM of SKI-5C inhibited 
cell proliferation of both triple-negative MDA-MB-231 
and ER-positive MCF-7 cells within 48 hours, but did 
not affect normal breast epithelial MCF-10A cells (Fig. 
3C). We also compared the use of SKI-5C (SPHK1-
specific inhibitor) and DMS (N,N-dimethyl-sphingosine) 
(a SPHK1 and SPHK2 dual-inhibitor). We observed that 
SKI-5C was more effective in inhibiting proliferation of 
MDA-MB-231 as its baseline SPHK1 level is high. In 
MCF-7 and MCF-10A cell lines, which have lower levels 
of SPHK1 expression, the inhibition of cell viability by 
SKI-5C and DMS were not significantly different. In 
addition, MCF-10A cells that have high SPHK2 levels, 
responded to SKI-5C and DMS treatment equally, 
suggesting that inhibition of SPHK2 had little or no effect 
on cell viability (Supplementary Data Fig. 4A) These 
results indicate that the inhibition of SPHK1 activity by 
SKI-5C effectively impairs the growth potential of breast 
cancer cells. 
Inhibition of SPHK1 activity impairs colony 
formation and breast tumor formation of MDA-
MB-231 cells in vivo
We investigated the effects of down-regulating 
SPHK1 levels by siRNA knockdown in the triple-negative 
MDA-MB-231 on colony formation ability. For this 
purpose, two siRNA constructs that target SPHK1 were 
used in triple-negative MDA-MB-231 cells (SPHK1 
Figure 5:SKI-5C inhibits the serum-dependent activation of ERK1/2 and AKT signalling and S1P export. Western 
blots showing the effect of SKI-5C on serum-dependent activation of ERK1/2 and AKT in MDA-MB-231 cells stimulated with 10% FBS 
for 5 - 120 minutes after treatment with 10µM SKI-5C. Control cells were stimulated with 10% FBS after pretreatment with DMSO. (B) 
Secreted S1P levels determined by ELISA in MDA-MB-231 cells pretreated with 10µM SKI-5C, followed by stimulation with 10% FBS 
for up to 240 minutes. Control cells were pretreated with DMSO. Data are expressed as mean ± S.D. of triplicate measurements and of 
three independent experiments; *p < 0.01. (C) Representative Western blot (of three independent experiments) showing the effect of PTX 
on serum induced ERK1/2 and AKT phosphorylation. 
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siRNA 1 and SPHK1 siRNA 2), and their effects compared 
to control siRNA. SPHK1 protein was reduced more 
effectively by SPHK1 siRNA 2 compared to siRNA1, 
which corresponded to significant reductions in the 
number of colonies formed compared to cells transfected 
with control siRNA (Fig. 4A-B). 
We next determined the effects of the SPHK1 
pharmacological inhibitor SKI-5C on the colony formation 
ability of breast cancer cells. Triple-negative MDA-
MB-231 cells were treated with SKI-5C in concentrations 
of 5-25μM for 7 days and colony formation was measured. 
There was a significant dose-dependent reduction in the 
number of colonies formed by SKI-5C-treated cells 
compared to control cells (Fig. 4C). These results indicate 
that the inhibition of SPHK1 activity by siRNA silencing 
or pharmacological inhibitor SKI-5C effectively impairs 
the growth potential of TNBC cells. We also investigated 
the effects of down-regulating SPHK2 levels by SPHK2 
siRNA. Results showed that SPHK2 siRNA knockdown 
in breast cancer cell did not affect colony formation and 
cell proliferation (Supplementary Data Fig. 5A-C). This 
provides further evidence that SPHK2 is not likely to have 
significant effects on growth and survival of breast cancer 
cells. 
To determine the therapeutic potential of 
pharmacologic inhibition of SPHK1 in TNBC, the 
effects of SKI-5C on tumor formation by MDA-
MB-231 cells were examined using a xenograft model in 
immunodeficient mice. MDA-MB-231 cells were injected 
subcutaneously and bilaterally into the flanks of SCID 
mice [25]. Treatment with daily intra-peritoneal injections 
of SKI-5C at 1 and10mg/kg was instituted from day 7 
for 14 consecutive days, and compared with control mice 
injected with saline. Treatment with SKI-5C significantly 
decreased tumor growth compared to control (Fig. 4D). 
After 14 days, the mean volume of the MDA-MB-231 
tumors, in mice treated with 10mg/kg SKI-5C, was less 
than 50% of the tumors in the control mice (control group 
mean = 631mm3 ±12.297, SKI-5C-10mg/kg body weight 
= 318mm3 ±17.125; P = 1.01568E-11). After 14 days of 
treatment, all mice were sacrificed and the subcutaneous 
tumors were extracted and weighed. Tumor weights of 
SKI-5C-treated mice were significantly lower than the 
control mice (Fig. 4E). We also examined the tumors by 
histological analysis. Tumors from control mice stained 
strongly for proliferating cell nuclear antigen (PCNA), 
indicating high proportions of proliferating cells in control 
tumors compared to SKI-5C-treated tumors. In contrast, 
immunohistochemical analysis of tumors from SKI-5C 
treated mice revealed a high proportion of apoptotic cells 
compared to control tumors as determined by nuclear 
fragmentation (TUNEL staining) (Fig. 4F). In summary, 
our results indicate that inhibition of SPHK1 is effective in 
suppressing the growth of triple-negative breast tumors in 
vitro and in vivo, suggesting that SPHK1 could be a useful 
therapeutic target in TNBC.
Serum induces pro-survival signals via SPHK1 
The extracellular signal-regulated kinases (ERK1/2) 
and PI3-kinase/AKT are major pathways regulating key 
cellular processes including proliferation, cell cycle 
progression and cell survival. 10% FBS was used to 
stimulate SPHK1 activity and examine the SPHK1-
dependent mechanisms induced by serum for breast cancer 
cell survival. Treatment of triple-negative MDA-MB-231 
cells with SKI-5C caused a rapid and sustained decrease 
in serum-induced phosphorylation of both ERK1/2 and 
AKT and SKI-5C inhibited early as well as sustained 
activation of ERK1/2 and AKT (Fig. 5A). The regulation 
of both ERK1/2 and AKT activation in response to serum 
stimulation could represent potential mechanisms by 
which SPHK1 promotes survival in breast cancer cells.
The biological functions of SPHK1 relies primarily 
on its product, S1P, which functions as an intracellular 
second messenger and ligand for the G protein-coupled 
S1P receptors [26]. We found that secreted S1P levels 
were significantly increased within 30 minutes of serum 
stimulation in MDA-MB-231 cells, and this increase was 
inhibited by 10µM SKI-5C (Fig. 5B). This indicates that 
SPHK1 activation is required for S1P production and 
release from the serum-stimulated cells.
Activation of ERK1/2 and AKT by agents that act 
through G protein-coupled receptors is often mediated by 
Gi proteins, and is therefore sensitive to pertussis toxin 
(PTX), which inhibits the function of Gi proteins [26]. To 
ascertain if S1P receptors are involved in serum-dependent 
ERK1/2 and AKT phosphorylation, MDA-MB-231 cells 
were stimulated with 10% FBS in the presence of PTX 
(100ng/ml for 2 hours). PTX inhibited the sustained 
activation of ERK1/2 and AKT by serum stimulation but 
did not affect the early activation of both pathways (Fig. 
5C). These findings suggest that the sustained activation 
of ERK1/2 and AKT by serum requires S1P secretion and 
S1P-receptor stimulation. 
SPHK1 inhibition enhances efficacy of 
chemotherapeutic treatment in breast cancer cells
Microarray analysis was performed on 65 breast 
tumors from patients with locally advanced or metastatic 
cancers who were recruited into a prospective study on 
Doxorubicin and Docetaxel-based chemotherapy. We 
observed significantly higher SPHK1 mRNA levels in 
patients who were non-responders to treatment compared 
to complete or partial responders (p=0.021) (Fig. 6A). 
Non-responders achieved only stable or progressive 
disease as their best response (WHO criteria) after 6 
cycles of chemotherapy. This suggests that SPHK1 may 
be a useful predictor of chemotherapy response, and may 
contribute to chemotherapy resistance.
We investigated the effectiveness of combining 
Oncotarget5927www.impactjournals.com/oncotarget
Doxorubicin and 5-FU with SPHK1 knockdown or 
inhibition by SKI-5C in ER-negative breast cancer 
cells. MDA-MB-231 cells transfected with SPHK1 
siRNA or control siRNA were exposed to either 5-FU 
or Doxorubicin before being harvested for PI analysis 
by flow cytometry. Whilst silencing of SPHK1 in MDA-
MB-231 cells induced a small but significant increase in 
cell death of about 20%, the combination with 5-FU or 
Doxorubicin induced further synergistic increases in cell 
death of about 60% compared to treatment with either 
drug alone (20% cell death) (Fig. 6B). 
The combination of SKI-5C with Doxorubicin, 5-FU 
and Docetaxel used at doses below IC50 (Supplementary 
data Fig. 6A) was also examined. When MDA-MB-231 
cells were pre-treated with 10µM SKI-5C, cell death was 
significantly enhanced, with synergistic increases of up to 
Figure 6: SPHK1 affects breast cancer sensitivity to Doxorubicin and 5-FU. (A) Comparison of baseline SPHK1 levels 
between clinical non-responders and responders to Doxorubicin-based treatment (8212±14901 vs 2948±3411, p=0.021). (B) Percentages 
of sub-G1 population by PI analysis in cells transfected with either control siRNA or SPHK1 siRNA1 for 48 hours (p = 0.00024), followed 
by addition of 20µM 5-FU or 10µM Doxorubicin for 24 hours. Data are expressed as mean ± S.D. of triplicate measurements and of 
three independent experiments; * p < 0.05 compared to SPHK1 siRNA 1, # p < 0.05 compared to 5-FU or Doxorubicin (Student’s t- test). 
(C-E) Sub-G1 populations by PI analysis in combination treatment of cells using 10µM SKI-5C with low doses (below IC50) of 1-10µM 
Doxorubicin or 2 - 20µM 5-FU or 10-50nM Docetaxel for 24 hours compared to treatment with either SKI-5C, Doxorubicin, 5-FU or 
Docetaxel alone. Data represents the mean ± SD of at least three independent experiments; *p < 0.05.
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43.8% cell death with 10µM Doxorubicin, 35% cell death 
with 20µM 5-FU and 66% cell death with 50nM Docetaxel 
(Fig. 6C-E). The combination of SKI-5C and Doxorubicin 
or Docetaxel was also carried out in another triple negative 
breast cancer cell line Hs578T, which similarly yielded 
significant increases in cell death compared to each drug 
alone (Supplementary Data Fig. 6B-C). 
DISCUSSION
Numerous studies have shown that SPHK1 is 
critical for growth, metastasis and chemo-resistance 
of human breast cancers [27]. Previous work in breast 
cancer has shown that SPHK1 is activated by estrogen 
signaling and promotes estrogen-dependent oncogenesis 
[28, 29]. However, the basal molecular subtype of breast 
cancers, which often lack the ER receptor and are thus 
unresponsive to anti-estrogens, have been found to express 
high baseline expression levels of SPHK1. This subtype 
of breast cancers has been reported to be more aggressive 
and bear a poorer survival outcome. Therefore, this study 
is focused on evaluating SPHK1 as a potential therapeutic 
target for treatment of basal breast carcinoma patients. 
On the other hand, the role of SPHK2 in cancer is still 
largely unknown. It has been reported that over-expression 
of SPHK2 decreases cell growth and enhances apoptosis 
[30], which seems to suggest that it may function as a 
tumor suppressor. 
In our studies, up-regulation of SPHK1 in TNBC 
was identified by several lines of evidence, including 
comparative determination of SPHK1 expression in breast 
cancer tissues and cell lines, as well as microarray data 
of human breast cancers from Affymetrix U133A and 
U133Plus2 platforms. Our study has provided evidence 
that SPHK1 up-regulation plays important roles in the 
growth and survival of TNBC cells. Furthermore, our 
microarray analysis revealed significantly elevated levels 
of SPHK1 in poor responders to Doxorubicin/Doxetaxel-
based chemotherapy, showing that SPHK1 may play a 
critical role in breast cancer resistance to chemotherapy.
In TNBC cells, SKI-5C reduced serum-induced 
growth and survival mediated through ERK1/2 and 
AKT pathways, indicating that TNBC cells are sensitive 
to SPHK1 inhibition. We show that activation of these 
pathways in response to serum is executed by different 
SPHK1-dependent mechanisms. The activation of ERK1/2 
and AKT signaling depends on both the intracellular S1P 
production by SPHK1, as well as the SPHK1-dependent 
secretion of S1P acting on G protein-coupled receptors 
which functions to sustain ERK1/2 and AKT signaling. 
Recently, SPHK1 was shown to increase S1P export from 
ER-positive breast cancer cells in response to estrogen 
[31]. In ER-positive breast cancer patients, recent 
evidence also indicates that the activation of SPHK1 and 
SPHK1-mediated pathways, including S1P and ERK1/2, is 
associated with endocrine resistance and earlier recurrence 
[32]. Our data indicates that SPHK1 activity is also crucial 
for S1P export from TNBC cells in response to serum 
stimulation. As both early and sustained phases of ERK1/2 
and AKT signaling are sensitive to SKI-5C, SPHK1 
inhibitors are effective against proliferative responses to 
intracellular S1P, as well as secondary stimulation from 
S1P secretion. There is evidence that activated ERK1/2 
can also phosphorylate and activate SPHK1 [33]. It is thus 
possible that a positive feedback loop exists, whereby 
activated ERK1/2 stimulates SPHK1, leading to increased 
intracellular S1P as well as S1P export. Exported S1P then 
in turn stimulates ERK1/2 via S1P receptors, leading to 
sustained activation of both ERK1/2 as well as SPHK1. 
As both ERK1/2 and SPHK1 have been implicated in 
several oncogenic pathways, the inhibition of SPHK1 by 
SKI-5C may effectively down-regulate multiple molecular 
pathways in breast cancer by its potential to interrupt this 
positive feedback loop. Therefore, these data provide 
further evidence for the pharmacological inhibition of 
SPHK1 as a potential therapeutic strategy in the treatment 
of TNBC. 
In vitro, SPHK1 siRNA knockdown enhanced the 
cytotoxic effects of Doxorubicin and 5-FU in TNBC cells. 
This is consistent with our observations of elevated SPHK1 
in patients who respond poorly to Doxorubicin. Our data 
suggests that the combination of SPHK1 inhibitors with 
conventional chemotherapeutic drugs could be effective 
against TNBCs. Indeed, levels of tumor cytotoxicity 
observed using low doses of Doxorubicin, 5-FU and 
Docetaxel were appreciably enhanced by combination 
with SKI-5C. This is supported by emerging evidence 
in other cancers showing the enhanced cytotoxicity of 
conventional chemotherapeutic agents upon inhibiting 
SPHK1 [16, 34, 35]. To extend the clinical application 
of this strategy, breast cancer patients who exhibit poor 
response to Doxorubicin-based chemotherapy may benefit 
from SPHK1-targeted therapy as the significantly higher 
levels of SPHK1 in their tumors may be conferring tumor-
survival advantages. 
In summary, our studies indicate that SPHK1 is a 
potential therapeutic target not only in ER-positive breast 
cancers, which have been previously reported, but also 
TNBCs. We validated the higher expression of SPHK1 
mRNA levels in triple-negative human breast tumors 
compared to receptor-positive tumors, which correlate 
with poor overall and progression-free survival in breast 
cancer patients. Importantly, we also observed that poor 
patient response to Doxorubicin-based treatment is 
significantly associated with high SPHK1 levels. Using 
xenograft and in vitro models, we demonstrate that 
inhibition of SPHK1 in TNBC cells reduces growth and 
attenuates signaling mechanisms in TNBC cells through 
S1P, ERK1/2 and AKT pathways. Furthermore, SPHK1 
inhibition sensitizes TNBC cells to chemotherapeutic 
agents such as Doxorubicin, 5-FU and Docetaxel. The 
development of SPHK1-targeted drugs should thus be 
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further explored to improve the treatment and prognosis 
of patients with TNBCs. 
MATERIALS AND METHODS
Materials
We synthesized 2,2-dimethyl-4S-(1-oxo- 
2-hexadecyn-1-yl)-1,1-dimethylethylester-3-oxazolidine 
carboxylic acid (SKI-5C), a specific inhibitor of SPHK1, 
as previously described [36]. SKI-5C is also available 
from Cayman Chemical (CAY10621). Doxorubicin, 
5-FU and pertussis toxin (PTX) were purchased from 
Sigma. SPHK1 antibody was purchased from Exalpha 
Biologicals Inc; GAPDH antibody was from Santa Cruz 
Biotechnologies (CA, USA) and phospho-ERK1/2, 
ERK1/2, phospho-AKT, AKT antibodies were from Cell 
Signaling Technology Inc, USA.
Cell lines and tissues
Human mammary and breast cancer cell lines 
including MCF10A, MCF7, MDA-MB-231, SKBr3, BT-
474, BT-549 and Hs578T were obtained from American 
Type Culture Collection (ATCC, USA), and maintained at 
37ºC with 5% CO2 in growth medium MEGM (Mammary 
Epithelial cell growth medium), DMEM (Dulbecco’s 
Modified Eagle’s Medium) and RPMI-1640 respectively 
supplemented with 10% fetal bovine serum (FBS). 32 
human breast tumor tissues and adjacent normal breast 
tissues were obtained from NUH-NUS Tissue Repository 
for real-time PCR measurement of SPHK1 levels.
For serum stimulation, cells were plated in serum-
free media in 6-well plates at a density of 105 cells/well 
for 14 hours. Subsequently, cells were pretreated with 
inhibitors for 15 minutes before stimulation with 10% 
FBS. Samples were lysed in RIPA buffer (50mM Tris-
HCL, pH7.4; 1% NP-40; 0.25% Na-deoxycholate; 150mM 
NaCl; 1mM EDTA) with protease and phosphatase 
inhibitors (Roche, USA). Lysates were used for Western 
blot analysis and measurement of sphingosine kinase 
activity.
Analysis of SPHK1 expression in clinical 
therapeutics cohort
For the clinical therapeutics analysis, female 
patients with histologically or cytologically proven locally 
advanced or metastatic breast cancer were recruited 
into a prospective phase II study and randomized to 
one of two alternating sequences of Doxorubicin (A) 
and Docetaxel (T), starting either with Doxorubicin 
75mg/m2 or Docetaxel 75mg/m2 every 3 weeks for six 
cycles (A-T-A-T-A-T, n=49; T-A-T-A-T-A, n=51). The 
study protocol was approved by the institutional ethics 
committee (National Healthcare Group Domain Specific 
Review Board), and all patients provided written informed 
consent. Clinical response was categorized according to 
the WHO criteria into complete response, partial response, 
stable disease and progressive disease after 6 cycles of 
chemotherapy. Tumor core biopsies were taken from each 
patient at baseline for immunohistochemical analysis for 
estrogen receptor and transcription analysis for SPHK1. 
Total tumor RNA was labelled by biotin and hybridized 
on the Affymetrix U133+2 microarray chip and analyzed 
according to the manufacturer’s instructions (Santa Clara, 
California, USA), and tumor SPHK1 expression data 
(probe set 219257s_at) extracted for this analysis. The 
gene expression data for this study is publicly available 
at the Centre for Information Biology Gene Expression 
Database (CIBEX, http://cibex.nig.ac.jp/index.jsp; CIBEX 
Accession number: CBX91). The clinical trial was 
registered with clinicaltrials.gov (ClinicalTrials.gov ID: 
NCT00212082).
Quantitative real-time PCR (RT-PCR)
Total RNA was extracted using the RNeasy Mini 
Kit (Qiagen), according to the manufacturer’s protocol 
and 500ng of total RNA was converted to cDNA per 20µl 
reaction using ImProm-IITM Reverse Transcription System 
(A3803, Promega). Real-time PCRs were performed 
with an ABI Prism 7300 Real time PCR system (Applied 
Biosystems) using custom Taqman Gene Expression 
Assay. Data were normalized to GAPDH. A two-tailed 
Student t-test was used to calculate statistical significance.
Data preprocessing of Affymetrix microarray for 
SPHK1 gene expression
Microarray data of human breast cancer on 
Affymetrix U133A or U133Plus2 platforms were 
downloaded from Array Express and Gene Expression 
Omnibus (GEO). In order for our study to be consistent 
with broader generalization and attain a larger sample 
size, we did not impose limit on age, stage, tumor grade or 
lymph node status. We included all primary or metastatic 
breast cancer patients (age > 20) found on GEO at the 
time the study is initiated.  We checked the distribution 
of grade, ER status, HER2 status, lymph node status, and 
age in SPHK1-low and high groups in OS and PFS. The 
panel of human breast cancer data utilized for analysis 
comprises 3,992 tumor samples from 26 cohorts, including 
E-TABM-158 (n=130), GSE11121 (n=200), GSE12276 
(n=204), GSE1456 (n=159), GSE1561 (n=49), GSE19615 
(n=115), GSE20181 (n=176), GSE2034 (n=286), 
GSE21653 (n=266), GSE23177 (n=116), GSE23593 
(n=50), GSE23988 (n=61), GSE25066 (n=508), 
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GSE26639 (n=226), GSE31519 (n=67), GSE3494 
(n=251), GSE3744 (n=47), GSE4922 (n=40), GSE5327 
(n=58), GSE5460 (n=127), GSE5764 (n=10), GSE6532 
(n=414), GSE6596 (n=24), GSE7390 (n=198), GSE9195 
(n=77), and HESS cohort (n=133) [37]. Out of the 3,992 
tumor samples, 974 have overall survival information, and 
2,333 have progression-free survival information.  Robust 
Multichip Average (RMA) normalization was performed 
on each dataset. The normalized data was combined and 
subsequently standardized using ComBat [38] to remove 
batch effect. 
Western blot analysis
Equal amounts of protein were separated by SDS-
PAGE and transferred to polyvinylidene difluoride 
membranes (PVDF) (Millipore, USA). Blots were 
incubated with primary antibodies against SPHK1, 
GAPDH, phospho-ERK1/2, ERK1/2, phospho-AKT and 
AKT, followed by appropriate HRP-conjugated secondary 
antibodies. Immunocomplexes were visualized by ECL 
Western blot analysis detection system (Amersham 
Biosciences). 
Measurement of sphingosine kinase activity 
(fluorometric method)
The protocol has previously been established [39]. 
70µg of protein was incubated with 20µM of 15-NBD-
Sph (prepared as a complex with BSA) and ATP (1mM) 
in SPHK buffer (50mM 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid, pH 7.4, containing 15mM MgCl2, 
0.005% Triton X-100, 10mM KCl). After incubation 
for 30 minutes at 370C, 100µl 1M potassium phosphate 
buffer (pH 8.5) was added, followed by 500µl CHCL3/
MeOH 2:1. After brief mixing, phases were separated by 
centrifugation, the upper aqueous layer was removed and 
placed into polystyrene microplates (Greiner Bio-One), 
followed by addition of 75µl dimethylformamide (Merck). 
Fluorescence intensity was measured at 485/535nm.
Cell proliferation, cell viability and colony 
formation
Cell proliferation was ascertained by plating cells 
at a density of 2000 cells/well in 96-well plates, then 
proliferation was measured using the BrdU proliferation 
assay (Roche). The optical densities (O.D) at 450nm for 
both untreated and treated cells measured at the start of 
the assay (‘0’ hours) were taken as 1. The relative fold 
changes in O.D. (450nm) for untreated and treated 
cells at 6, 24, and 48 hours were calculated against 
their respective ‘0 hour’ control cells, and expressed as 
‘Relative Proliferation’. For cell viability assays, 104 cells 
were plated in 96-well plates. Cell viability was measured 
using the WST-1 assay (Roche). The ability for colony 
formation at low cell density was determined by plating 
1000 cells into 6-well plate and culturing for 7 days. Cells 
were subsequently stained with 0.5% crystal violet in 
30% ethanol, 3% formaldehyde for 10 minutes at room 
temperature. Stained colonies were imaged and counted 
by Image J software. 
Cell death analysis 
Cells (105/well in 2ml) were grown overnight with 
10% FBS, incubated with 5-50µM SKI-5C for 24 hours, 
fixed with 70% ethanol and stained with propidium 
iodide (0.1% Triton X-100, 200ug/ml RNase A, 20ug/ml 
propidium iodide in PBS). Detection of sub-G1 (dead) 
cells was performed using flow cytometry. For detection of 
apoptotic cells, surface expression of phosphatidylserine 
was assessed using Annexin-V–Fluos kit (Roche). SKI-
5C-treated cells were re-suspended in PBS with FITC-
conjugated Annexin-V. Flow cytometry analysis was 
conducted using the BD FACSCalibur and Cell Quest Pro 
Software.
Measurement of S1P 
Extracellular S1P levels were measured using 
S1P competitive ELISA with a sensitivity of 30nM S1P 
(Echelon Bioscience Inc). Cells (105/well in 2ml) were 
plated without FBS for 14 hours, then pretreated with 
inhibitors for 15 minutes before stimulation with 10% FBS 
for up to 240 minutes. The supernatant was collected for 
S1P analysis by manufacturer’s instructions.
siRNA transfection 
The siRNAs (Qiagen) were transfected into cells 
using Lipofectamine RNAi Max (Invitrogen), according 
to manufacturer’s protocol. After 6 hours, transfection 
medium was removed and replaced with fresh complete 
medium. Cells were harvested after 48 hours of 
transfection.
Tumor xenograft model 
All experiments involving mice were conducted in 
accordance with NUS Institutional Animal Care and Use 
committee (Approved IACUC Protocol No: 108/06A409) 
guidelines which approves the use of animal (mice) for 
research. Female severe combined immunodeficient 
(SCID) mice (weighing 7 to 8 gm) aged 8 to 10 weeks, 
were obtained from Biological Resource Centre (BRC) 
Agency for Science, Technology and Research (A* STAR) 
Biopolis. MDA-MB-231 cells (2 x 106 suspended in 100 
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µL sterile PBS) were injected subcutaneously into 2 sites 
on both flanks of SCID mice and allowed to grow for 6 
days. To determine the size of the subcutaneous tumors, 
we used the ellipsoid volume formula [40, 41], an accurate 
estimation of actual tumor volume [42] which has been 
applied by other laboratories in several breast cancer 
xenograft models [43, 44]. Tumor measurements were 
made daily with calipers, and tumor volume was calculated 
using the formula: (π x [length in millimetres] x [width in 
millimeters2]/6. On day 7, mice were randomly assigned 
to different groups that were injected intra-peritoneally 
(i.p.) with 100 µl saline (control) (n=6) and SKI-5C at 
dose of 10mg/kg BW (n=6) for 14 consecutive days. At 
the end of the experiment, the animals were sacrificed and 
tumors were removed for measurement of tumor weight 
and fixed in formalin, and embedded in paraffin. Sections 
were de-paraffinised and rehydrated and were stained with 
hematoxylin-eosin or with antibodies against proliferating 
cell nuclear antigen (PCNA) (DakoCytomation). 
Apoptotic cells were detected by ApopTag Peroxidase in 
situ Apoptosis Detection Kit (Chemicon international). 
Staining was visualized using DAB (DakoCytomation) 
and counter-stained by methyl green.
Statistical Analysis
The statistical significance of difference was 
evaluated using the unpaired Student’s t-test. The tests 
were two-sided and level of significance was set at *p 
<0.05. 
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